DESMOPRESSIN ACETATE
LOE ApproachingNDAORALTABLET
Approved
May 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
DESMOPRESSIN ACETATE by Ferring Pharmaceuticals is 2 (v2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. First approved in 2008.
Drug data last refreshed 7h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Desmopressin acetate is a synthetic analogue of arginine vasopressin indicated for primary nocturnal enuresis, available as an oral tablet. It works by enhancing antidiuretic activity, reducing urinary output and increasing urine osmolality to control bedwetting. The oral formulation has approximately 5% bioavailability compared to intranasal administration, with onset of effect at ~1 hour and maximum effect at 4-7 hours.
LOE Approaching
As LOE approaches, the brand team will likely focus on lifecycle management and transition planning, with potential consolidation of commercial resources.
Mechanism of Action
2 (V2) receptors, thereby increasing water re-absorption in the kidney, and hence reducing urine production. Desmopressin is a replacement hormone for antidiuretic hormone in the treatment of central diabetes insipidus. The change in structure of arginine vasopressin to desmopressin acetate…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Desmopressin Acetate 0.2 mg Tablets, Fasting
Started Jul 2003
48 enrolled
Healthy
Career Relevance
Desmopressin acetate offers limited career growth given its LOE stage and mature market position; opportunities are concentrated in commercial teams managing market defense and competitive pricing. Roles focusing on lifecycle management, generic transition, and cost optimization will be most relevant.
Worked on DESMOPRESSIN ACETATE at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.